Format

Send to

Choose Destination
Oncotarget. 2016 Oct 11;7(41):66865-66879. doi: 10.18632/oncotarget.11784.

β-escin selectively targets the glioblastoma-initiating cell population and reduces cell viability.

Author information

1
CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, F-44000, France.
2
Team SOAP, "Signaling in Oncogenesis, Angiogenesis, and Permeability", Nantes, F-44000, France.

Abstract

Glioblastoma multiforme (GBM) is a highly aggressive tumour of the central nervous system and is associated with an extremely poor prognosis. Within GBM exists a subpopulation of cells, glioblastoma-initiating cells (GIC), which possess the characteristics of progenitor cells, have the ability to initiate tumour growth and resist to current treatment strategies. We aimed at identifying novel specific inhibitors of GIC expansion through use of a large-scale chemical screen of approved small molecules. Here, we report the identification of the natural compound β-escin as a selective inhibitor of GIC viability. Indeed, β-escin was significantly cytotoxic in nine patient-derived GIC, whilst exhibiting no substantial effect on the other human cancer or control cell lines tested. In addition, β-escin was more effective at reducing GIC growth than current clinically used cytotoxic agents. We further show that β-escin triggers caspase-dependent cell death combined with a loss of stemness properties. However, blocking apoptosis could not rescue the β-escin-induced reduction in sphere formation or stemness marker activity, indicating that β-escin directly modifies the stem identity of GIC, independent of the induction of cell death. Thus, this study has repositioned β-escin as a promising potential candidate to selectively target the aggressive population of initiating cells within GBM.

KEYWORDS:

apoptosis; chemical screen; glioblastoma-initiating cells; self-renewal; temozolomide

PMID:
27589691
PMCID:
PMC5341843
DOI:
10.18632/oncotarget.11784
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center